Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Interius Biotherapeutics Doses First Patient With In Vivo Chimeric Antigen Receptor Car Gene Therapy For B Cell Malignancies is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Kite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy
SANTA MONICA, CA & PHILADELPHIA, PA — Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in vivo chimeric antigen ... Read More
Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition
Gilead Sciences broke into the field of cancer cell therapies through an acquisition. Now it’s aiming to be part of the next generation of such therapies by buying clinical-stage Interius ... Read More
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy
Kite will acquire Interius BioTherapeutics for $350 million, expanding into in vivo CAR T therapies. The deal is expected to cut Gilead’s 2025 EPS by 23-25 cents per share. Want to trade this news? Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus